These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7865186)

  • 1. Clinical aspects of cardiomyopathy in dialysis patients.
    Parfrey PS; Harnett JD
    Blood Purif; 1994; 12(4-5):267-76. PubMed ID: 7865186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].
    Portolés J; López-Gómez JM; Aljama P
    Nefrologia; 2005; 25(3):297-306. PubMed ID: 16053011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hypertension in renal failure patients: when do we overtreat? When do we undertreat?
    Rosansky SJ
    Blood Purif; 1996; 14(4):315-20. PubMed ID: 8873957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of erythropoietin on cardiovascular diseases.
    Sunder-Plassmann G; Hörl WH
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S20-5. PubMed ID: 11576916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients.
    Massimetti C; Pontillo D; Feriozzi S; Costantini S; Capezzuto A; Ancarani E
    Blood Purif; 1998; 16(6):317-24. PubMed ID: 10343078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management of cardiac disease in chronic uremia.
    Parfrey PS; Harnett JD
    Curr Opin Nephrol Hypertens; 1994 Mar; 3(2):145-54. PubMed ID: 7842264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of acute coronary syndrome in a large Canadian cohort: impact of chronic renal insufficiency, cardiac interventions, and anemia.
    Keough-Ryan TM; Kiberd BA; Dipchand CS; Cox JL; Rose CL; Thompson KJ; Clase CM
    Am J Kidney Dis; 2005 Nov; 46(5):845-55. PubMed ID: 16253724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiac function and hematocrit level.
    Harnett JD; Kent GM; Foley RN; Parfrey PS
    Am J Kidney Dis; 1995 Apr; 25(4 Suppl 1):S3-7. PubMed ID: 7702071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of renal transplantation on uremic cardiomyopathy.
    Parfrey PS; Harnett JD; Foley RN; Kent GM; Murray DC; Barre PE; Guttmann RD
    Transplantation; 1995 Nov; 60(9):908-14. PubMed ID: 7491692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The natural history of myocardial disease in dialysis patients.
    Parfrey PS; Harnett JD; Barre PE
    J Am Soc Nephrol; 1991 Jul; 2(1):2-12. PubMed ID: 1832984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.
    Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP
    Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome and risk factors of ischemic heart disease in chronic uremia.
    Parfrey PS; Foley RN; Harnett JD; Kent GM; Murray D; Barre PE
    Kidney Int; 1996 May; 49(5):1428-34. PubMed ID: 8731110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Left ventricular hypertrophy in end-stage renal disease and its possible regression as a result of correction of anemia and arterial hypertension].
    Dzgoeva FU; Gatagonova TM; Kadzaeva ZK; Khamitsaeva OV; Kochisova ZKh; Dzutseva AT; Bazaeva BG
    Ter Arkh; 2011; 83(6):42-6. PubMed ID: 21786575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
    Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
    Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy.
    Foley RN; Parfrey PS; Harnett JD; Kent GM; Martin CJ; Murray DC; Barre PE
    Kidney Int; 1995 Jan; 47(1):186-92. PubMed ID: 7731145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome and risk factors for left ventricular disorders in chronic uraemia.
    Parfrey PS; Foley RN; Harnett JD; Kent GM; Murray DC; Barre PE
    Nephrol Dial Transplant; 1996 Jul; 11(7):1277-85. PubMed ID: 8672023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for cardiac morbidity and mortality in dialysis patients.
    Foley RN; Parfrey PS
    Curr Opin Nephrol Hypertens; 1994 Nov; 3(6):608-14. PubMed ID: 7881984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients.
    Kuriyama S; Tomonari H; Yoshida H; Hashimoto T; Kawaguchi Y; Sakai O
    Nephron; 1997; 77(2):176-85. PubMed ID: 9346384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis.
    deFilippi C; Wasserman S; Rosanio S; Tiblier E; Sperger H; Tocchi M; Christenson R; Uretsky B; Smiley M; Gold J; Muniz H; Badalamenti J; Herzog C; Henrich W
    JAMA; 2003 Jul; 290(3):353-9. PubMed ID: 12865376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood pressure and cardiovascular mortality in dialysis patients with left ventricular systolic dysfunction.
    Losito A; Del Vecchio L; Del Rosso G; Malandra R;
    Am J Hypertens; 2014 Mar; 27(3):401-8. PubMed ID: 24108864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.